跳至主要内容
临床试验/NCT07096258
NCT07096258招募中不适用

A Patient Registry Collecting the Clinical and Molecular Profiling Data of Patients With Locally Advanced and/or Metastatic, Unresectable, Stages IIIB/C or IV Non-small Cell Lung Cancer (NSCLC), Who Have Not Previously Been Treated for This Advanced Disease and Are Therefore Considered as Patients Receiving First-line Therapy.

Hedera Dx SA4 个研究点 分布在 4 个国家目标入组 1,000 人开始时间: 2024年6月1日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
4
主要终点
Actionable biomarkers

研究概览

简要总结

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
  • Intention-to-initiate first-line tumour therapy for this advanced disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤
  • At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

排除标准

  • Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

结局指标

主要结局

Actionable biomarkers

时间窗: At baseline

Proportion of patients with successful molecular profiling and detectable actionable biomarkers

次要结局

未报告次要终点

研究者

发起方
Hedera Dx SA
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

EMPATHY NSCLC: European Registry for Plasma-Based... | 临床试验